Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group-Reference-Cited by-同舟云学术

Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group

Published:2024-07 Issue:7 Volume:25 Page:912-921
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Gupta Abha A,Xue Wei,Harrison Douglas J,Hawkins Douglas S,Dasgupta Roshni,Wolden Suzanne,Shulkin Barry,Qumseya Amira,Routh Jonathan C,MacDonald Tamara,Feinberg Shari,Crompton Brian,Rudzinski Erin R,Arnold Michael,Venkatramani Raj

Funder

Saint Baldricks Foundation

National Cancer Institute

Children’s Oncology Group

NIH

Publisher

Elsevier BV

Reference27 articles.

1. Soft tissue and bone tumours,2020

2. Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group;Rudzinski;Am J Clin Pathol,2013

3. Feasibility of combining temsirolimus to vincristine, dactinomycin, cyclophosphamide, and vincristine and irinotecan chemotherapy for children with intermediate-risk rhabdomyosarcoma: a report from Children's Oncology Group;Oberoi;Pediatr Blood Cancer,2023

4. Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995,1999

5. An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials;Haduong;Pediatr Blood Cancer,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Randomised trials in children with rhabdomyosarcoma: time for a change?;The Lancet Oncology;2024-07